Blueprint Medicines Co. (NASDAQ:BPMC) Receives $124.95 Average Target Price from Analysts

Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-three brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $124.95.

Several research analysts recently commented on BPMC shares. Wedbush restated an "outperform" rating and issued a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Stephens restated an "overweight" rating and set a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. JMP Securities reiterated a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Jefferies Financial Group began coverage on Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 price objective on the stock. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $133.00 target price on shares of Blueprint Medicines in a research note on Thursday, February 13th.

Blueprint Medicines Trading Up 7.4 %

Shares of NASDAQ:BPMC traded up $6.55 during midday trading on Friday, reaching $95.27. The company's stock had a trading volume of 1,348,765 shares, compared to its average volume of 711,495. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The firm has a market cap of $6.09 billion, a price-to-earnings ratio of -88.21 and a beta of 0.58. The business has a 50 day moving average price of $99.47 and a 200 day moving average price of $93.89. Blueprint Medicines has a 1 year low of $80.68 and a 1 year high of $121.90.

Remove Ads

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. Research analysts forecast that Blueprint Medicines will post -1.28 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Kate Haviland sold 1,446 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now directly owns 149,378 shares of the company's stock, valued at approximately $16,467,430.72. This represents a 0.96 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total transaction of $250,458.36. Following the completion of the transaction, the chief operating officer now directly owns 67,109 shares of the company's stock, valued at approximately $7,391,385.26. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,334 shares of company stock valued at $3,103,512 in the last quarter. Insiders own 4.21% of the company's stock.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors and hedge funds have recently bought and sold shares of the business. Torray Investment Partners LLC boosted its stake in Blueprint Medicines by 1.1% in the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock valued at $1,439,000 after acquiring an additional 186 shares during the period. Sherbrooke Park Advisers LLC boosted its position in Blueprint Medicines by 8.4% during the 4th quarter. Sherbrooke Park Advisers LLC now owns 3,374 shares of the biotechnology company's stock valued at $294,000 after purchasing an additional 261 shares during the period. Franklin Resources Inc. boosted its position in Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after purchasing an additional 265 shares during the period. Summit Investment Advisors Inc. grew its stake in Blueprint Medicines by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock worth $580,000 after buying an additional 283 shares during the last quarter. Finally, Pitcairn Co. increased its position in Blueprint Medicines by 2.8% in the fourth quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock worth $925,000 after buying an additional 293 shares during the period.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.